vs

Side-by-side financial comparison of MIDDLEFIELD BANC CORP (MBCN) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $19.9M, roughly 1.8× MIDDLEFIELD BANC CORP). MIDDLEFIELD BANC CORP runs the higher net margin — 26.7% vs -304.2%, a 331.0% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 18.3%). MIDDLEFIELD BANC CORP produced more free cash flow last quarter ($3.4M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 13.7%).

Star Banc Corporation was a Cincinnati, Ohio-based regional bank holding company that acquired Firstar in 1998 and took the Firstar name; the merged bank acquired U.S. Bancorp in 2001 and took the U.S. Bancorp name. The company can trace its origins back to 1863 when it was first founded as the First National Bank of Cincinnati.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MBCN vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.8× larger
RXRX
$35.5M
$19.9M
MBCN
Growing faster (revenue YoY)
RXRX
RXRX
+663.5% gap
RXRX
681.7%
18.3%
MBCN
Higher net margin
MBCN
MBCN
331.0% more per $
MBCN
26.7%
-304.2%
RXRX
More free cash flow
MBCN
MBCN
$50.7M more FCF
MBCN
$3.4M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
13.7%
MBCN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
MBCN
MBCN
RXRX
RXRX
Revenue
$19.9M
$35.5M
Net Profit
$5.3M
$-108.1M
Gross Margin
59.8%
Operating Margin
32.2%
-304.8%
Net Margin
26.7%
-304.2%
Revenue YoY
18.3%
681.7%
Net Profit YoY
127.4%
39.6%
EPS (diluted)
$0.65
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MBCN
MBCN
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$19.9M
$5.2M
Q2 25
$20.5M
$19.2M
Q1 25
$18.0M
$14.7M
Q4 24
$17.5M
$4.5M
Q3 24
$16.8M
$26.1M
Q2 24
$16.8M
$14.4M
Q1 24
$16.8M
$13.8M
Net Profit
MBCN
MBCN
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$5.3M
$-162.3M
Q2 25
$6.2M
$-171.9M
Q1 25
$4.8M
$-202.5M
Q4 24
$4.8M
$-178.9M
Q3 24
$2.3M
$-95.8M
Q2 24
$4.2M
$-97.5M
Q1 24
$4.2M
$-91.4M
Gross Margin
MBCN
MBCN
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
MBCN
MBCN
RXRX
RXRX
Q4 25
-304.8%
Q3 25
32.2%
-3327.6%
Q2 25
35.9%
-916.8%
Q1 25
31.9%
-1297.9%
Q4 24
33.4%
-4042.4%
Q3 24
16.1%
-377.1%
Q2 24
28.8%
-697.4%
Q1 24
29.4%
-698.4%
Net Margin
MBCN
MBCN
RXRX
RXRX
Q4 25
-304.2%
Q3 25
26.7%
-3135.3%
Q2 25
30.0%
-894.2%
Q1 25
26.8%
-1373.3%
Q4 24
27.8%
-3935.5%
Q3 24
13.9%
-367.5%
Q2 24
24.7%
-676.6%
Q1 24
24.9%
-662.4%
EPS (diluted)
MBCN
MBCN
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$0.65
$-0.36
Q2 25
$0.76
$-0.41
Q1 25
$0.60
$-0.50
Q4 24
$0.60
$-0.56
Q3 24
$0.29
$-0.34
Q2 24
$0.52
$-0.40
Q1 24
$0.51
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MBCN
MBCN
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$224.1M
$1.1B
Total Assets
$2.0B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MBCN
MBCN
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
MBCN
MBCN
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
MBCN
MBCN
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$224.1M
$1.0B
Q2 25
$216.1M
$919.1M
Q1 25
$213.8M
$933.9M
Q4 24
$210.6M
$1.0B
Q3 24
$210.7M
$524.6M
Q2 24
$206.8M
$584.4M
Q1 24
$205.6M
$401.2M
Total Assets
MBCN
MBCN
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$2.0B
$1.4B
Q2 25
$1.9B
$1.3B
Q1 25
$1.9B
$1.3B
Q4 24
$1.9B
$1.4B
Q3 24
$1.9B
$726.5M
Q2 24
$1.8B
$775.9M
Q1 24
$1.8B
$557.8M
Debt / Equity
MBCN
MBCN
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MBCN
MBCN
RXRX
RXRX
Operating Cash FlowLast quarter
$4.8M
$-46.1M
Free Cash FlowOCF − Capex
$3.4M
$-47.3M
FCF MarginFCF / Revenue
17.0%
-133.1%
Capex IntensityCapex / Revenue
7.2%
3.5%
Cash ConversionOCF / Net Profit
0.91×
TTM Free Cash FlowTrailing 4 quarters
$32.0M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MBCN
MBCN
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$4.8M
$-117.4M
Q2 25
$4.8M
$-76.4M
Q1 25
$8.0M
$-132.0M
Q4 24
$17.5M
$-115.4M
Q3 24
$6.0M
$-59.2M
Q2 24
$3.4M
$-82.2M
Q1 24
$5.4M
$-102.3M
Free Cash Flow
MBCN
MBCN
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$3.4M
$-117.6M
Q2 25
$4.2M
$-79.6M
Q1 25
$7.7M
$-133.8M
Q4 24
$16.7M
$-116.7M
Q3 24
$5.8M
$-63.8M
Q2 24
$3.3M
$-83.4M
Q1 24
$5.3M
$-109.0M
FCF Margin
MBCN
MBCN
RXRX
RXRX
Q4 25
-133.1%
Q3 25
17.0%
-2272.5%
Q2 25
20.5%
-413.9%
Q1 25
42.9%
-907.4%
Q4 24
95.6%
-2567.7%
Q3 24
34.7%
-244.6%
Q2 24
19.3%
-578.5%
Q1 24
31.9%
-789.9%
Capex Intensity
MBCN
MBCN
RXRX
RXRX
Q4 25
3.5%
Q3 25
7.2%
4.7%
Q2 25
3.0%
16.4%
Q1 25
1.5%
12.4%
Q4 24
4.4%
28.6%
Q3 24
1.0%
17.5%
Q2 24
0.6%
8.2%
Q1 24
0.5%
48.2%
Cash Conversion
MBCN
MBCN
RXRX
RXRX
Q4 25
Q3 25
0.91×
Q2 25
0.78×
Q1 25
1.66×
Q4 24
3.60×
Q3 24
2.57×
Q2 24
0.81×
Q1 24
1.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons